Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 311-317

  Gallego, Rosa ^a   Codony Servat, Jordi ^a   García Albéniz, Xabier ^a   Carcereny, Enric ^a   Longarón, Raquel ^a   Oliveras, Angeles ^a   Tosca, Mónica ^a   Augé, Josep Maria ^a   Gascón, Pedro ^a   Maurel, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; MATRILYSIN; OXALIPLATIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAMPTOTHECIN; DRUG DERIVATIVE; FOLFOX PROTOCOL; IFL PROTOCOL; IGFBP3 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; PLATINUM COMPLEX; SOMATOMEDIN BINDING PROTEIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPOTHESIS; IMMUNOASSAY; MALE; OVERALL SURVIVAL; PROTEIN DEGRADATION; TREATMENT OUTCOME; BLOOD; COLORECTAL TUMOR; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LEUCOVORIN; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 65549157036     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0250     Document Type: Article

References (33)

1. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR & Kley N 1995 Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377 646-649.
2. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L & Lewis CE 2003 Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. American Journal of Pathology 163 1233-1243.
3. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R & Murray GI 2004 Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clinical Cancer Research 10 8229-8234.
4. Davies M, Gupta S, Goldspink G & Winslet M 2006 The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. International Journal of Colorectal Disease 21 201-208.
5. Furstenberger G, Senn E, Morant R, Bolliger B & Senn HJ 2006 Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 15 64-68.
6. Grimberg, A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P & El-Deiry WS 2005 p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. Journal of Clinical Endocrinology and Metabolism 90 3568-3574.
7. Helle SI, Geisler S, Aas T, Paulsen T, Holly JM & Lonning PE 2001 Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. British Journal of Cancer 85 74-77.
8. Hemers E, Duval C, McCaig C, Handley M, Dockray GJ & Varro A 2005 Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling. Cancer Research 65 7363-7369.
9. Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI & Evans BD 2003 Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. Australian and New Zealand Journal of Surgery 73 905-908.
10. Jenkins PJ, Khalaf S, Ogunkolade W, McCarthy K, David T, Hands RE, Davies D & Bustin SA 2005 Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis. Endocrine-Related Cancer 12 891-901.
11. Jones JI & Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 16 3-34.
12. Kajdaniuk D & Marek B 2000 Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients. Journal of Clinical Pharmacy and Therapeutics 25 67-72.
13. Kummel S, Eggemann H, Lueftner D, Gebauer N, Buehler H, Schaller G, Schmid P, Kreienberg R, Emons G, Kriner M et al. 2007 Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes. International Journal of Biological Markers 22 186-193.
14. Kurokawa S, Arimura Y, Yamamoto H, Adachi Y, Endo T, Sato T, Suga T, Hosokawa M, Shinomura Y & Imai K 2005 Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut 54 1751-1758.
15. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH & Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute 91 620-625.
16. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria AJ, Longaron R et al. 2007 Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. International Journal of Cancer 121 1066-1071.
17. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP & Fuchs CS 2005 Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention 14 1402-1410.
18. Michell NP, Dent S, Langman MJ & Eggo MC 1997 Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors 14 269-277.
19. Miraki-Moud F, Jenkins PJ, Fairclough PD, Jordan S, Bustin SA, Jones AM, Lowe DG, Monson JP, Grossman AB, Besser GM et al. 2001 Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly. Clinical Endocrinology 54 499-508.
20. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T & Ochiai A 2004 Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Research 64 665-671.
21. Miyamoto S, Nakamura M, Yano K, Ishii G, Hasebe T, Endoh Y, Sangai T, Maeda H, Shi-Chuang Z, Chiba T et al. 2007 Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Science 98 685-691.
22. Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M & Ochiai A 2005 Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochemical and Biophysical Research Communications 333 1011-1016.
23. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK & Majumdar AP 2008 Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. International Journal of Cancer 122 267-273.
24. Peyrat JP, Revillion F & Bonneterre J 1998 Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy. British Journal of Cancer 77 1669-1671.
25. Pollak MN, Schernhammer ES & Hankinson SE 2004 Insulin-like growth factors and neoplasia. Nature Reviews. Cancer 4 505-518.
26. Pommier G, Garrouste F, el Atiq F, Marvaldi J & Remacle-Bonnet M 1993 Potential role of IGFBPS in the regulation of the differentiation state of human colonic carcinoma cells. Growth Regulation 3 80-82.
27. Sabha N, Aitken K, Lorenzo AJ, Szybowska M, Jairath A & Bagli DJ 2006 Matrix metalloproteinase-7 and epidermal growth factor receptor mediate hypoxia-induced extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase activation and subsequent proliferation in bladder smooth muscle cells. In Vitro Cellular & Developmental Biology. Animal 42 124-133.
28. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, Naitou M, Doihara H, Kisimoto T, Katayama H et al. 2007 Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. International Journal of Cancer 120 566-573.
29. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM & Paraskeva C 2000 Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Research 60 22-27.
30. Williams AC, Smartt H, Zadeh AM, Macfarlane M, Paraskeva C & Collard TJ 2007 Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death and Differentiation 14 137-145.
31. Zadeh SM & Binoux M 1997 The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 138 3069-3072.
32. Zadeh AM, Collard TJ, Malik K, Hicks DJ, Paraskeva C & Williams AC 2006 Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. International Journal of Oncology 29 1279-1286.
33. Zeng ZS, Shu WP, Cohen AM & Guillem JG 2002 Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clinical Cancer Research 8 144-148.